Challenges
- •Resources directed away from AMR surveillance
- •Increase in pre-emptive antibiotic prescribing to prevent secondary bacterial infections
- •Antibiotic overuse in agribusiness
- •Delays in AMR legislation
- •Antimicrobial drug shortages
- •Empty pharmaceutical pipeline
- •USA withdrawal of support for WHO
- •Low public awareness of AMR
- •Crisis fatigue
Opportunities
- •Subsidise hospital AMR surveillance
- •Integrate AMR risk into investment practices
- •Prioritise antimicrobial stewardship programmes
- •Develop rapid diagnostics
- •Embrace One Health approach
- •Ban medically important antibiotics in agribusiness
- •Promote consumer and supplier/private sector awareness and action on food choices
- •Pass legislation (eg, DISARM and PASTEUR Acts)
- •Incentivise new antibiotics and other promising anti-infectives
- •Strengthen global collaboration and governance architecture
- •Enact PACCARB and UN IACG recommendations
- •Develop collaborative public information campaigns
- •Leverage infection control principles from COVID-19 experience
Source: Confronting antimicrobial resistance beyond the COVID-19 pandemic and the 2020 US election, The Lancet publication
